A new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas (TCGA) Research Network has identified markers of aggressive tumors, which could allow for better targeting of appropriate treatments to individual patients. The finding suggests the potential to reclassify the disease based on genetic markers and moves thyroid cancer into a position to benefit more from precision medicine.
“This understanding of the genomic landscape of thyroid cancer will refine how it’s classified and improve molecular diagnosis. This will help us separate those patients who need aggressive treatment from those whose tumor is never likely to grow or spread,” says Thomas J. Giordano, MD, PhD, professor of pathology at the University of Michigan Medical School in Ann Arbor.
Giordano is the project co-lead for TCGA thyroid cancer analysis along with Gad Getz, PhD, director of Cancer Genome Computational at the Broad Institute in Boston, Massachusetts.
Thyroid cancer incidence has increased three-fold over the last 30 years and is the most rapidly increasing cancer in the United States. Although the tumors are often slow-growing and easily treated with a combination of surgery, thyroid hormone, and radioactive iodine, some patients develop more aggressive and deadly thyroid cancers.
In this TCGA study, published in Cell (2014;159:676-690), the researchers analyzed nearly 500 thyroid cancer samples to identify all genetic mutations that play a role. They found several new cancer genes as well as new variations of existing genes.
Overall, the thyroid cancer genome is relatively quiet, with fewer genetic mutations involved than in other common cancers, the researchers found. This may explain why the disease is often slow-growing.
Fewer mutations meant the researchers were able to look at the signaling pathways involved and understand what drives thyroid tumors. This approach helped them understand the genetic drivers of more of these cancers, reducing the percentage of dark matter cases, which are those with unknown genetic drivers, from 25% to 3.5%.
Those drivers can be broken down into two primary oncogenic groups: BRAF plus similar mutations and RAS plus similar mutations. But within these two primary groups, especially the BRAF group, several different subtypes of thyroid cancer exist. Currently, all thyroid cancers associated with BRAF, for example, had been considered essentially the same. That’s not the case.
“This study integrated a wide variety of genomic data to not only identify cancer drivers, but to compare how these different drivers behave,” said Getz. “Interestingly, we found that subsets of BRAF-mutated thyroid cancers are driving cancer through distinct mechanisms, and that some of these subsets are associated with higher risk and less differentiated cancers.”
The researchers used this understanding to create measures or scores that can determine how a tumor signals and how aggressive a thyroid tumor is. These scores are being tested in a clinical trial to assess if it can lead to more targeted treatment recommendations.
An initial recommendation is for the pathology and scientific communities to consider reclassifying thyroid cancer based on molecular subtypes to better reflect their underlying molecular properties. This would allow doctors to identify the slow-growing tumors from the aggressive tumors and recommend appropriate treatments.